In fact, a recently reported randomized phase III trial that compared two CNI-free approaches (CD34-selected grafts and PTCy) to standard CNI-based GvHD prevention, with tacrolimus and methotrexate, showed that grafting after PTCy was slower compared to the others [51]. This evidence concerns the gene CD34 and graft versus host disease.